TD Cowen Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price ...
Axsome Therapeutics, Inc.: Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...
Axsome Therapeutics settles Sunosi patent litigation with Hikma
Axsome Therapeutics (AXSM) announced that it has entered into a settlement agreement with Hikma Pharmaceuticals (HKMPF), resolving patent ...
Axsome resolves patent dispute with Hikma
Axsome Therapeutics (AXSM) stock gains as company settles patent dispute with Hikma (HKMPF) over sleep therapy Sunosi. Read ...
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...
Drug Store News2d
Hikma releases mercaptopurine oral suspension
Mercaptopurine oral suspension is indicated for the treatment of patients with acute lymphoblastic leukemia as part of a ...
Hikma Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 5.3% growth forecast ...